The STEP-CAT Cohort Management Study: Step-down to Prophylactic Doses of Enoxaparin After a Minimum of 3-6 Months of Anticoagulation for the Treatment of Cancer-associated Thrombosis
Latest Information Update: 26 May 2022
At a glance
- Drugs Enoxaparin sodium (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Thrombosis; Venous thromboembolism
- Focus Therapeutic Use
- Acronyms STEP-CAT
- 19 May 2022 Results assessing feasibility of extended prophylactic-dose low-molecular-weight heparin (LMWH) treatment following a minimum of three months of full-dose LMWH, published in the Journal of Thrombosis and Haemostasis
- 21 Nov 2018 Status changed from recruiting to discontinued.
- 17 Aug 2018 Planned End Date changed from 1 May 2018 to 1 May 2019.